Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that patients with alopecia areata had significantly higher systemic immune-inflammation index levels compared to healthy controls, regardless of the disease's severity.

This case report highlights that improper application techniques, such as scalp occlusion, can increase systemic absorption of minoxidil and lead to unwanted side effects like hypertrichosis.

This case study highlights the importance of considering systemic lupus erythematosus in young patients presenting with atypical symptoms like periorbital erythema and pancytopenia, as early diagnosis and treatment can lead to remission.

Systemic minoxidil improves hair density in women with female pattern hair loss over time.

In this narrative review, the authors concluded that while high-quality evidence for systemic therapies in pediatric alopecia areata is scarce, Janus kinase inhibitors have the most systematic support, with oral minoxidil and dupilumab also reported as potentially beneficial in certain cases.

This study concluded that laser hair removal using Alexandrite laser emitting red and infrared light appears safe and does not significantly affect the disease activity of Systemic lupus erythematosus.

In this study conducted at a tertiary care hospital, the researchers observed that alopecia areata was more prevalent in males aged 21-30, typically presenting as single patches, with anemia being the most common associated systemic condition and lichen planus the most associated dermatological condition.

This case report describes a rare occurrence of pincer nail deformity in a patient with systemic lupus erythematosus, potentially linked to Raynaud's phenomena as a contributing factor.

This case report describes the first successful use of telitacicept in treating a patient with systemic lupus erythematosus and a history of papillary thyroid carcinoma, suggesting its potential as a therapeutic option for such conditions.

This case report describes a 27-year-old female with systemic lupus erythematosus who presented with chilblain lupus erythematosus and melanonychia striata, emphasizing the rarity of such presentations in SLE patients.

This study reported that primary care physicians' lack of knowledge about rheumatology and referrals to other specialties are major factors delaying systemic lupus erythematosus patients' access to rheumatology care in India.

This review discusses the disparities in approved treatments and evidence-based guidelines for various chronic skin diseases, highlighting greater unmet medical needs in conditions like hidradenitis suppurativa, alopecia areata, and vitiligo compared to psoriasis and atopic dermatitis.

In this case study, a woman with SLE and severe alopecia showed improved hair growth using intralesional triamcinolone, PRP injections, and tacrolimus ointment, highlighting PRP as a potential adjunct therapy for inflammatory alopecia.

Glucocorticoid treatment in lupus can cause oral lesions, which need early diagnosis and comprehensive care.

This study investigated adverse events from low-dose systemic minoxidil in an older population with hair loss and found that 19% experienced mainly facial and body hypertrichosis, managed with interventions like dose reduction and diuretics; no serious adverse events occurred.

This case report describes a 54-year-old Saudi woman with systemic lupus erythematosus and severe alopecia, where conventional treatments were ineffective. When belimumab was ineffective, baricitinib led to significant improvement in her condition, suggesting further research is needed to evaluate baricitinib's role in managing SLE.

This case report describes a woman whose psychiatric symptoms preceded the clear signs of systemic lupus erythematosus, which could suggest they were early indicators of SLE or related to an underlying mental disorder exacerbated by SLE.

This case report identified a connection between idiopathic intracranial hypertension, papilledema, and newly diagnosed systemic lupus erythematosus in a young woman, highlighting the importance of thorough system reviews in such circumstances.

This study found that systemic lupus erythematosus predominantly affects young adults, with diverse symptoms including mucocutaneous and renal involvement, and highlights the significance of early detection for improved management.

PRO-C22 can help diagnose and monitor the severity of hidradenitis suppurativa.

This case report detailed a 45-year-old woman with diffuse systemic sclerosis who underwent Ayurvedic treatment, leading to reduced depigmentation, new hair growth, and improved well-being over eight weeks. The findings suggest the potential efficacy of a holistic Ayurvedic approach in managing scleroderma symptoms.

In this case report, a 17-year-old girl with systemic lupus erythematosus presented with seizure-induced vocal cord palsy and gradually improved with treatment involving steroids, immunosuppressives, and speech therapy.

In this case study, a 25-year-old presented with symptoms of lupus but tested negative for antinuclear antibodies, complicating diagnosis. The researchers emphasize that comprehensive diagnostic approaches, beyond ANA testing, are vital for effectively identifying and treating lupus nephritis to avoid serious outcomes.

Tailored treatments for alopecia areata show promising results, with pulse steroids effective for mild cases and Ritlecitinib, Dupilumab, or methotrexate and prednisone effective for severe cases.

This study found that systemic treatment with DS77754007, a KLK5 inhibitor, improved skin symptoms in a mouse model of Netherton Syndrome more effectively than certain antibody treatments, suggesting KLK5 inhibition as a promising therapeutic approach for this condition.

This case report describes a 27-year-old female diagnosed with subacute cutaneous lupus erythematosus, who experienced improvement in symptoms following treatment, including fading of skin lesions.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

This study provides insights into systemic lupus erythematosus patients' experiences with Anifrolumab, highlighting improvements in symptoms and health-related quality of life, despite ongoing daily life impacts.

This study explored the experiences of systemic lupus erythematosus patients receiving Anifrolumab, revealing improvements in self-reported symptoms and daily life impacts alongside decreased disease activity and lowered corticosteroid use.